Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06409026 · ClinicalTrials.gov registry record · Phase 4
Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension
A Phase 4 study of Pulmonary Arterial Hypertension, sponsored by Mayo Clinic.
- Active
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06409026: Active Phase 4 study of Pulmonary Arterial Hypertension, sponsored by Mayo Clinic.
NCT06409026 is a Phase 4 study of Pulmonary Arterial Hypertension that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 30 participants, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06409026, a Phase 4 study of Pulmonary Arterial Hypertension, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if the drug sotatercept given for 36 weeks improves the functioning of the heart and improves quality of life.
Primary Outcome
Peak exercise pulmonary arterial mean pressure/ Cardiac output (mm Hg/L/min)
Conditions Studied
Interventions
- DRUG Sotatercept
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-07-05 |
| Est. Completion | 2026-03 |
| Phase | Phase 4 |
What the registry record for NCT06409026 still lists
NCT06409026 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Sotatercept is the first listed.
NCT06409026 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06409026 about?
NCT06409026 is a clinical study titled "Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension". The purpose of this study is to see if the drug sotatercept given for 36 weeks improves the functioning of the heart and improves quality of life.
What is the current status of trial NCT06409026?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2024-07-05. Estimated completion is 2026-03.
What conditions does trial NCT06409026 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.
What interventions are being tested in trial NCT06409026?
The interventions under investigation include: Sotatercept (DRUG).
Who is sponsoring clinical trial NCT06409026?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06409026 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06409026's enrollment target sits among peer trials
30 41st of 63 higher than 20 of 63 other Pulmonary Arterial Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Arterial Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 4
-
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
COMPLETED · Phase 4
-
Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication
COMPLETED · Phase 4
-
Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401
COMPLETED · Phase 4
-
Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension
COMPLETED · Phase 4
-
Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI